期刊
BREAST
卷 30, 期 -, 页码 197-200出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2016.06.016
关键词
Breast cancer; Sentinel lymph node biopsy (SLNB); Axillary lymph node dissection (ALND); Overall survival (OS); SINODAR ONE
Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据